Literature DB >> 16299941

Zoledronic acid(ZOMETA): a significant improvement in the bone metastases.

Zsuzsanna Nagy1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16299941     DOI： 10.1007/bf02893400

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


× No keyword cloud information.
  9 in total

Review 1.  Bisphosphonates: from the laboratory to the clinic and back again.

Authors:  R G Russell; M J Rogers
Journal:  Bone       Date:  1999-07       Impact factor: 4.398

2.  Progress in the management of bone metastases: one continent at a time?

Authors:  Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

Review 3.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies.

Authors:  R E Coleman
Journal:  Cancer Treat Rev       Date:  2001-06       Impact factor: 12.111

Review 4.  Clodronate: a review of its use in breast cancer.

Authors:  M Hurst; S Noble
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

5.  Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

Authors:  Norio Kohno; Kenjiro Aogi; Hironobu Minami; Seigo Nakamura; Taro Asaga; Yuichi Iino; Toru Watanabe; Carsten Goessl; Yasuo Ohashi; Shigemitsu Takashima
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

6.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

Authors:  R L Theriault; A Lipton; G N Hortobagyi; R Leff; S Glück; J F Stewart; S Costello; I Kennedy; J Simeone; J J Seaman; R D Knight; K Mellars; M Heffernan; D J Reitsma
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

7.  Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.

Authors:  Lee S Rosen; David Gordon; Mary Kaminski; Anthony Howell; Andrew Belch; John Mackey; Justus Apffelstaedt; Mohamad A Hussein; Robert E Coleman; Dirk J Reitsma; Bee-Lian Chen; John J Seaman
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

Review 8.  Zoledronic acid: a review of its use in patients with advanced cancer.

Authors:  Caroline M Perry; David P Figgitt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Direct effects of bisphosphonates on breast cancer cells.

Authors:  Siddhika G Senaratne; Kay W Colston
Journal:  Breast Cancer Res       Date:  2001-11-14       Impact factor: 6.466
  9 in total
  4 in total

1.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Authors:  Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher
Journal:  Lancet Oncol       Date:  2010-03-31       Impact factor: 41.316

Review 2.  Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.

Authors:  John A Carter; Avani D Joshi; Satyin Kaura; Marc F Botteman
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

Review 3.  Zoledronic acid : a review of its use in the management of bone metastases of malignancy.

Authors:  Sohita Dhillon; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.

Authors:  Wei-Wei Huang; Cheng Huang; Jian Liu; Hong-Yu Zheng; Lin Lin
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.